BeiGene Files 8-K for Regulatory and Exhibit Disclosures

TL;DR

BeiGene filed a routine 8-K on Jan 13, 2025, for Reg FD and exhibits. No major news.

AI Summary

BeiGene, Ltd. filed an 8-K on January 13, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates but serves as a procedural disclosure.

Why It Matters

This filing indicates BeiGene is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This is a standard procedural filing with no new material information that would typically impact risk.

Key Players & Entities

• BeiGene, Ltd. (company) — Registrant
• Mourant Governance Services (Cayman) Limited (company) — Agent for service of process
• January 13, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Selec

Filing Documents

• bgne-20250113.htm (8-K) — 37KB
• 0001651308-25-000012.txt ( ) — 158KB
• bgne-20250113.xsd (EX-101.SCH) — 2KB
• bgne-20250113_lab.xml (EX-101.LAB) — 21KB
• bgne-20250113_pre.xml (EX-101.PRE) — 12KB
• bgne-20250113_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, BeiGene, Ltd. (the "Company") participated in the 43rd Annual J.P. Morgan Healthcare Conference and announced that the Company expects to achieve positive operating income for full year 2025 pursuant to U.S. generally accepted accounting principles. This guidance does not assume any potential new, material business development activity or unusual/non-recurring items. An archived replay of the presentation can be accessed from the Investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/ and will be available for 30 days following the event. The information furnished under Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the Company's ability to achieve positive operating income for full year 2025 pursuant to U.S. generally accepted accounting principles. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information herein is as of the date set forth above, and BeiGene undertakes no duty to update such information unless required by law.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: January 13, 2025 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR